Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Priority Review Vouchers Appear To Be Dropping In Price

Executive Summary

Gilead spent less than $338m for the coupon entitling it to a speedier FDA review, down at least $12m from AbbVie's high-water purchase price almost a year ago.

Advertisement

Related Content

Drug Pricing: Could Expedited Review Of Competing Brands Create The Desired Pressure?
Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?
Marathon's High-Priced Window May Not Stay Open Long
When Will Gilead Make Its M&A Move?
Keeping Track: KemPharm Apadaz Delay; Cholera Vaccine Approved
Priority Review Voucher Expansion Could Be Bad, Program Creator Says
Gilead Buys Nimbus NASH Drug To Dominate Another Liver Disease
Keeping Track: Imbruvica Snags First-Line CLL Claim; Gilead TAF Strategy Advances
Priority Review Voucher Not For Sale, Alexion Says After Strensiq Approval
With 29 Candidates Advancing, NASH Race May Hinge On Long-Duration Data

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118848

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel